Skip to main content
. 2021 Dec 22;9(5):2103812. doi: 10.1002/advs.202103812

Figure 4.

Figure 4

Evaluation of the capability of B1L@SpAcDex‐ATMO‐21 NPs to inhibit angiogenesis‐related genes and NP‐induced cell apoptosis. a) Proposed mechanism of as‐fabricated NPs for inhibiting the growth of tumor blood vessels. Modified icons from BioRender.com. b) Biocompatibility evaluation of B1L@SpAcDex‐ATMO‐21 NPs without ATMO‐21 when incubated with U87MG cells. Data are presented as means ± SD (n = 3). Or c) with ATMO‐21 when incubated with human astrocyte cells. Data are presented as means ± SD (n = 3). d) Relative protein expression of PTEN, p‐AKT, p‐ERK, HIF‐1α, and VEGF in U87MG cells in different treatment groups (phosphate buffered saline (PBS), naked ATMO‐21, SpAcDex‐ATMO‐21 NPs, B1L@SpAcDex‐ATMO‐21 NPs) evaluated by Western blotting (n = 3). e) Relative VEGF expression levels in different treatment groups in vitro via CLSM imaging. Scale bar, 10 µm. f) Relative miRNA‐21 expression levels in different treatment groups in vitro. Data are presented as means ± SD (n = 3, one‐way ANOVA, *p < 0.05, ***p < 0.001, n.s., nonsignificant). g) Cell viability of U87MG cells treated with as‐fabricated NPs at different concentrations. Data are presented as means ± SD (n = 3, one‐way ANOVA, *p < 0.05, ***p < 0.001). h) Flow cytometry evaluation of PI cell apoptosis. i) Live/dead cell imaging via CLSM. Scale bar, 100 µm.